NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner.
NorthX Biologics Secures Significant Growth Investment from Signet Healthcare Partners
NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity firm with deep expertise in pharmaceutical services. This strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines, and extending U.S. commercial reach.
